RESUMO
Objective: Role of 0.01% atropine in progressive myopia in children. Material and methods: After getting approval from the ethical committee of the Government medical college kota, we conducted a prospective study of 50 children from march 2021 to march 2022 for progressive myopia (>0.5 D/year) out of which 25 children got treatment in form of topical atropine 0.01%. The effectiveness of the drug was evaluated by calculating SE (Spherical Equivalent) at every visit. Mean change in SE was calculated before treatment and after treatment and a comparison of both the mean values was done for the efficacy of the drug. Results: Out of 25 treatment groups, 14 were males and 11 were females. There was 13 male and 12 female in the control group. The mean age was 9.7 years ± 2.3 years (range 5 years-14 years) and 12.1 years ± 2.9 years (6 years-16 years) in the atropine and control groups respectively. At baseline mean SE was found to be -2.9 ± 0.149 and -2.63 ± 0.268 whereas Best Corrected Visual Acuity (BCVA) was 0.438 ± 0.067 and 0.65 ± 0.14 in the atropine and control group respectively. The rate of myopia progression in study participants. The mean progression rate was found to be lower in the atropine group when compared before and after treatment (-0.97 ± 0.055 versus -0.23 ± 0.018). It was found to be 0.23 D/year which is supported by various previous studies like the atom 2 study in which myopic rate progression was 0.42 D after 12 months of atropine use. Conclusion: It can be concluded that 0.01% atropine eyedrops used once daily before bed can slow the progression of myopia with very good tolerance and few side effects, making it a recommended treatment to be included in our therapeutic routine.